Feed

Open sources, classified and cross-checked. 1,804+ stories.

All Conflict Military Politics Business Sci & Tech Cyber Disaster Health World

24h 3 days 7 days 30 days All·All regions North America South America Western Europe Eastern Europe Baltics Middle East North Africa Sub-Saharan Africa South Asia East Asia Oceania

POLITICSJun 16PM Modi holds bilateral talks with Kenya , Japan , Egypt and South Korea leaders on sidelines of G7 SummitPM Modi held bilateral talks with leaders from Kenya, Japan, Egypt, and South Korea during the G7 Summit. These discussions signify important diplomatic engagements on the international stage.kenyastar.com · Kenya

BUSINESSJun 16Japan Raises Interest Rates To 31 - Year High As War - Driven Energy Costs Fuel Inflation ConcernsJapan has raised interest rates to a 31-year high, driven by concerns over inflation fueled by war-related energy costs. This signifies a major economic policy shift influenced by global events.ibtimes.com · United States

SCI & TECHJun 16Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming LeadershipPluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicineglobenewswire_fr · france

SCI & TECHJun 16Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming LeadershipSEATTLE, June 16, 2026 (GLOBE NEWSWIRE) -- Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a Notice of Allowance for Patent Application No. 2023-552219. The licensed patent, titled "Engineered Expression Constructs to Increase Protein Expression from Synthetic Ribonucleic Acid (RNA)" (nationalization of International Application No. PCT/US2022/017880), represents a critical expansion of Pluristyx's intellectual property portfolio. These unique synthetic mRNA constructs stabilize mRNA and increase protein expression without need for modified nucleosides, microRNA sites, or immune-evading factors. This allowance comes at a pivotal moment for regenerative medicine in Japan. A global leader in induced pluripotent stem cell (iPSC) research, Japan established an accelerated regulatory framework for iPSC-derived products in 2015. More than 11 years later, the first two landmark commercial iPSC-derived cell therapies have been approved. Pluristyx is addressing this critical industry bottleneck in the transition from R&D to commercial use by applying its unique synthetic mRNA technology to rapidly generate safe, clinical-grade iPSCs able to be manufactured at large commercial scale. By optimizing expression kinetics of synthetic RNA with a multiplex of key pluripotency transcription factors, the Pluristyx platform ... Full story available on Benzinga.combenzinga · united states of america